ICCC · ImmuCell Corporation

This Settlement Deed concludes a contractual dispute stemming from the expiration of the 2019 Development Services and Commercial Supply Agreement, which had governed collaborative development and commercial supply activities between ImmuCell and Norbrook. The $2,000,000 payment represents a definitive resolution of outstanding claims without litigation or ongoing obligations, providing ImmuCell with a discrete cash inflow and eliminating potential future legal exposure or resource diversion. Because the underlying agreement had already expired—rather than being terminated early or breached—the settlement reflects a negotiated closure of residual matters rather than a material operational disruption or strategic reversal. The absence of admissions of liability and inclusion of confidentiality terms suggest both parties prioritized finality and reputational protection over public attribution of fault. While the amount is meaningful in absolute terms for a company of ImmuCell’s scale, the filing discloses no ongoing commercial relationship, revenue impact, or forward-looking commitments, limiting its strategic or operational implications beyond financial settlement and risk mitigation.